Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Osteoarthritis

Osteoporotic OA: a reasonable target for bone-acting agents

Nature Reviews Rheumatology volume 9, pages 448–450 (2013)Cite this article

Subjects

Beneficial effects of bone-acting drugs in osteoarthritis (OA) are increasingly reported, but reliable conclusions regarding their efficacy are hindered by methodological drawbacks in study design. Identifying patients with osteoporotic OA, a phenotype defined by decreased density associated with high remodelling in subchondral bone, might improve the success of bone-directed agents.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Increased subchondral bone remodelling and subsequent pathology are the target of anti-osteoporotic therapy in OA.

References

  1. Laslett, L. L., Kingsbury, S. R., Hensor, E. M., Bowes, M. A. & Conaghan, P. G. Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2012-202989

  2. Kwoh, C. K. Clinical relevance of bone marrow lesions in OA. Nat. Rev. Rheumatol. 9, 7–8 (2013).

    Article  Google Scholar 

  3. Goldring, S. R. & Goldring, M. B. Bone and cartilage in osteoarthritis: is what's best for one good or bad for the other? Arthritis Res. Ther. 12, 143 (2010).

    Article  Google Scholar 

  4. Bellido, M. et al. Subchondral bone microstructural damage by increased remodelling aggravates experimental osteoarthritis preceded by osteoporosis. Arthritis Res. Ther. 12, R152 (2010).

    Article  Google Scholar 

  5. Bellido, M. et al. Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. Osteoarthritis Cartilage 19, 1228–1236 (2011).

    Article  CAS  Google Scholar 

  6. Roemer, F. W. et al. Subchondral bone marrow lesions are highly associated with, and predict subchondral bone attrition longitudinally: the MOST study. Osteoarthritis Cartilage 18, 47–53 (2010).

    Article  CAS  Google Scholar 

  7. Herrero-Beaumont, G., Roman-Blas, J. A., Castañeda, S. & Jimenez, S. A. Primary osteoarthritis no longer primary: three subsets with distinct etiological, clinical, and therapeutic characteristics. Semin. Arthritis Rheum. 39, 71–80 (2009).

    Article  Google Scholar 

  8. Castañeda, S., Roman-Blas, J. A., Largo, R. & Herrero-Beaumont, G. What is osteoarthritis today? A progressive disease of changing phenotypes. Rheumatology (Oxford) (in press).

  9. Buckland-Wright, J. C., Messent, E. A., Bingham, C. O. 3rd, Ward, R. J. & Tonkin, C. A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients. Rheumatology (Oxford) 46, 257–264 (2007).

    Article  CAS  Google Scholar 

  10. Reginster, J. Y. et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann. Rheum. Dis. 72, 179–186 (2013).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors gratefully acknowledge the assistance of S. Castañeda from the Department of Rheumatology, Hospital de La Princesa, Madrid, Spain, and R. Largo from the Bone and Joint Research Unit, IIS Fundación Jiménez Díaz, Madrid, Spain, for the critical review of this manuscript. The authors' work is supported by research grants from the Instituto de Salud Carlos III (PI12/00144; PS09/01625).

Author information

Authors and Affiliations

  1. Bone and Joint Research Unit, Service of Rheumatology, IIS Fundación Jiménez Díaz, Universidad Autónoma, Av. Reyes Católicos 2, Madrid, 28040, Spain

    Gabriel Herrero-Beaumont & Jorge A. Roman-Blas

Authors
  1. Gabriel Herrero-Beaumont
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jorge A. Roman-Blas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gabriel Herrero-Beaumont.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herrero-Beaumont, G., Roman-Blas, J. Osteoporotic OA: a reasonable target for bone-acting agents. Nat Rev Rheumatol 9, 448–450 (2013). https://doi.org/10.1038/nrrheum.2013.113

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2013.113

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing